Monte Rosa Therapeutics, Inc.
$17.59
-0.85%Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -38.2).
Valuation inputs: P/E -38.2, earnings yield N/A, momentum -0.8%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -16.6%, ROIC -13.6%).
Profitability stack: net margin -31.2%, ROE -16.6%, ROIC -13.6%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +48.1%, momentum -0.8%, net margin -31.2%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Monte Rosa Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Monte Rosa Therapeutics, Inc. Fair Value Envelope
Monte Rosa Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Monte Rosa Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Monte Rosa Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Monte Rosa Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that GLUE stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 31.75, with estimates ranging from a low of 22.00 to a high of 37.00.
The consensus 1-year price target stands at 31.75, with estimates ranging from a low of 22.00 to a high of 37.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Monte Rosa Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.06M and sold $1.66M worth of GLUE shares, resulting in $605K of net selling activity.
3 Months
0
0.00
44.7K
829.17K
-829K
-$829K
3-6 Months
0
0.00
44.2K
830.67K
-831K
-$831K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
214.9K
1.06M
0
0.00
+1.1M
+$1.06M
Top Buyers
Behbahani Ali
Director, 10 Percent Owner:
$151K
Manning Anthony M.
Director
$151K
Blackwell Kimberly
Director
$151K
Siu Christine
Director
$151K
Skvarka Jan
Director
$151K
Top Sellers
Warmuth Markus
Director, Officer: President & Ceo
$526K
Dunn Edmund
Officer: Principal Accounting Officer
$467K
Manning Anthony M.
Director
$180K
Janku Filip
Officer: Chief Medical Officer
$179K
Townson Sharon
Officer: Chief Scientific Officer
$119K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $605K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
No Dividend Yield Data
GLUE has not reported any dividend yield values in the available annual periods.
glue Dividend History
Learning Layer
Related Guides
Build conviction on GLUE by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.